Boron nanoparticles inhibit tumour growth by boron neutron capture therapy in the murine B16-OVA model.
BACKGROUND
Boron neutron capture therapy usually relies on soluble, rather than particulate, boron compounds. This study evaluated the use of a novel boron nanoparticle for boron neutron capture therapy.


METHODS
Two hundred and fifty thousand B16-OVA tumour cells, pre-incubated with boron nanoparticles for 12 hours, were injected subcutaneously into C57BL/6J mice. The tumour sites were exposed to different doses of neutron radiation one, four, or eight days after tumour cell inoculation.


RESULTS
When the tumour site was irradiated with thermal neutrons one day after injection, tumour growth was delayed and the treated mice survived longer than untreated controls (median survival time 20 days (N = 8) compared with 10 days (N = 7) for untreated mice).


CONCLUSIONS
Boron nanoparticles significantly delay the growth of an aggressive B16-OVA tumour in vivo by boron neutron capture therapy.
Petersen
Mikkel Steen
MS
Department of Clinical Immunology, Aarhus University Hospital - Skejby, Brendstrupgaardvej 100, DK-8200 Aarhus N, Denmark. MWZ@sks.aaa.dk
Petersen
Charlotte Christie
CC
Agger
Ralf
R
Sutmuller
Marjolein
M
Jensen
Martin Roland
MR
Sørensen
Palle G
PG
Mortensen
Michael Wrang
MW
Hansen
Thomas
T
Bjørnholm
Thomas
T
Gundersen
Hans Jørgen
HJ
Huiskamp
René
R
Hokland
Marianne
M
D000818:Animals; D016754:Boron Neutron Capture Therapy / Q000379:methods*; D045744:Cell Line, Tumor; D005260:Female; D008546:Melanoma, Experimental / Q000517:prevention & control* / Q000532:radiotherapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D053758:Nanoparticles / Q000627:therapeutic use*; D009502:Neutrons / Q000627:therapeutic use*; D023041:Xenograft Model Antitumor Assays